Johnson & johnson strengthens neuroscience leadership with acquisition of intra-cellular therapies, inc.

Acquisition includes caplyta ® (lumateperone), the first and only u.s. fda-approved treatment for bipolar i and ii depression as an adjunctive and monotherapy; also approved for the treatment of schizophrenia in adults

ITCI Ratings Summary

ITCI Quant Ranking